Brokerages forecast that Aravive Inc (NASDAQ:ARAV) will announce sales of $2.10 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aravive’s earnings. The highest sales estimate is $3.19 million and the lowest is $1.00 million. Aravive posted sales of $1.37 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 53.3%. The company is scheduled to announce its next quarterly earnings results on Thursday, March 5th.
According to Zacks, analysts expect that Aravive will report full-year sales of $7.38 million for the current financial year, with estimates ranging from $4.80 million to $10.60 million. For the next year, analysts expect that the firm will report sales of $9.70 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Aravive.
Aravive (NASDAQ:ARAV) last posted its earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.04).
Several equities analysts recently weighed in on ARAV shares. Zacks Investment Research lowered shares of Aravive from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. ValuEngine upgraded shares of Aravive from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. HC Wainwright restated a “buy” rating on shares of Aravive in a report on Friday. Finally, Piper Jaffray Companies set a $15.00 price objective on shares of Aravive and gave the company a “buy” rating in a report on Friday, September 27th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Aravive has a consensus rating of “Buy” and a consensus target price of $13.69.
In related news, CEO Jay Shepard sold 4,004 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $6.82, for a total value of $27,307.28. Corporate insiders own 39.80% of the company’s stock.
A number of large investors have recently modified their holdings of ARAV. Artal Group S.A. increased its stake in Aravive by 20.0% in the second quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock valued at $1,845,000 after purchasing an additional 51,197 shares in the last quarter. Renaissance Technologies LLC increased its stake in Aravive by 13.8% in the second quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock valued at $890,000 after purchasing an additional 18,017 shares in the last quarter. BlackRock Inc. increased its stake in Aravive by 5.8% in the second quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock valued at $1,044,000 after purchasing an additional 9,544 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Aravive by 4.7% in the second quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock valued at $955,000 after purchasing an additional 7,200 shares in the last quarter. 28.35% of the stock is owned by hedge funds and other institutional investors.
NASDAQ ARAV traded up $0.01 on Thursday, reaching $6.53. The company’s stock had a trading volume of 5,300 shares, compared to its average volume of 23,717. The business has a 50-day moving average price of $7.03 and a 200 day moving average price of $6.27. Aravive has a 52 week low of $3.07 and a 52 week high of $9.72. The firm has a market cap of $75.95 million, a PE ratio of -0.61 and a beta of 2.17. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.17.
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
See Also: What is meant by holder of record?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.